Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
Holding IFRX?
Track your performance easily
IFRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.17 - $2.44
Previous Close$2.04
Volume312.81K
Average Volume (3M)136.58K
Market Cap
$113.06M
Enterprise Value$100.71M
Total Cash (Recent Filing)€12.77M
Total Debt (Recent Filing)€1.12M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Mar 20, 2025EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding58,883,272
10 Day Avg. Volume467,530
30 Day Avg. Volume136,576
Standard Deviation0.32
R-Squared0.07
Alpha0.00910
Financial Highlights & Ratios
Price to Book (P/B)1.17
Price to Sales (P/S)1608.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside288.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
InflaRx News
PremiumCompany Announcements
InflaRx Gets EMA Nod for COVID-19 Treatment
PremiumCompany Announcements
InflaRx Reports Q3 2024 Financial Results and Progress
PremiumCompany Announcements
InflaRx Reports Rising Revenue Amidst Significant LossesPremiumPre-Earnings
Is IFRX a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 3 clinical data showed a significant relative reduction in 28-day all-cause mortality of 23.9% versus placebo in critically ill invasively mechanically ventilated COVID-19 patients.
Financial StabilityIFRX had cash, cash equivalents, and marketable securities of €62.0M, expected to fund operations into 2026.
Regulatory ApprovalThe European Commission is expected to adopt a positive opinion and issue a marketing authorization for Gohibic.
Bears Say
Regulatory ChallengesThe FDA indicated that InflaRx would need to conduct an additional well-controlled and adequately powered study in a broader ARDS setting for it to obtain a biologics license application.
Resource AllocationInflaRx's commercialization approach for Gohibic in Europe implies limited resource allocation for the launch.
Sales PerformanceSales of Gohibic have materialized slower than expected, indicating low expected future sales for COVID-19.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
18.81% Other Institutional Investors
81.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $1.17 and its highest was $2.44 in the past 12 months.
What is InflaRx NV’s market cap?
Currently, no data Available
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Mar 20, 2025 which is in 118 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on Nov 08, 2024. The company reported -$0.318 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.053.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate is -$0.26.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 58,883,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.318 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 3.311%.
Which hedge fund is a major shareholder of InflaRx NV?
Among the largest hedge funds holding InflaRx NV’s share is Woodline Partners LP. It holds InflaRx NV’s shares valued at N/A.
---
InflaRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (288.35% Upside)
$8.00 (288.35% Upside)
Hedge Fund Trend
Decreased
By 173.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 23.3%
Last 30 Days ▲ 23.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.21%
12-Months-Change
Fundamentals
Return on Equity
-62.38%
Trailing 12-Months
Asset Growth
-35.13%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
---
IFRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(288.35% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Forte Biosciences
―
TG Therapeutics
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering IFRX
1 Year
1 Year Success Rate
14/28 ratings generated profit
1 Year Average Return
+9.56%
reiterated a buy rating 7 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +9.56% per trade.
---